Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the Netherlands
Abstract Background Use of the direct oral anticoagulant rivaroxaban has strongly increased in Europe since its market approval for non-valvular atrial fibrillation in 2011. Patients characteristics of rivaroxaban initiators may have changed over time but this has not been investigated so far. Objective We aimed to describe time trends of patient baseline characteristics among new rivaroxaban users with non-valvular atrial fibrillation from 2011 to 2016/17 in two European countries. Methods We used data from Germany (German Pharmacoepidemiological Research Database) and the Netherlands (PHARMO... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2023 |
Reihe/Periodikum: | Drugs - Real World Outcomes, Vol 10, Iss 2, Pp 215-224 (2023) |
Verlag/Hrsg.: |
Adis
Springer Healthcare |
Schlagwörter: | Therapeutics. Pharmacology / RM1-950 / Pharmacy and materia medica / RS1-441 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27191614 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.1007/s40801-022-00350-2 |